Christopher Rovaldi

Former President and Chief Operating OfficeratKeros Therapeutics· In proxies 2022–2025

Pay in FY2024+49% from the year before · Keros Therapeutics stock -60.2% the same year

Christopher Rovaldi was paid $7.0M in FY2024 (Dec), up 49%. Keros Therapeutics stock fell 60.2% that year.

Pay$100 in the stock at the end of FY21 → $27

Pay is from the Summary Compensation Table of each Keros Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

KROS
Keros TherapeuticsPublic company · 4 yr
- Former President and Chief Operating Officer2022 – Present · 4 yrStock in role -80%

Roles come from the proxy statements of each company.

Activity

Pay
Keros Therapeutics President pay rose 49% to $7.0M. The stock fell 60% in FY2024 (Dec).
DEF 14AApr 23, 2025
Pay
Keros Therapeutics President pay rose 10% to $4.7M. The stock fell 17% in FY2023 (Dec).
DEF 14AApr 17, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?